Epithelial Tenascin Predicts Obliterative Airway Disease

Journal of Heart and Lung Transplantation

Volumn 27, Issue 4, 2008, Pages 400-407

  Päiväniemi, Outi E ^a,b   Maasilta, Paula K ^a   Alho, Hanni S ^c   Vainikka, Tiina L S ^a   Salminen, Ulla Stina ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TENASCIN;

ALLOGRAFT; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CALCULATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIUM; FIBROBLAST; FIBROSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; ISCHEMIA; MACROPHAGE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; STATISTICAL SIGNIFICANCE; SWINE;

ANIMALS; BRONCHI; BRONCHIOLITIS OBLITERANS; BRONCHITIS; CELL PROLIFERATION; FIBROBLASTS; FIBROSIS; IMMUNOHISTOCHEMISTRY; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; RESPIRATORY MUCOSA; SWINE; TENASCIN; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 40949085584     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.01.009     Document Type: Article

References (40)

1. Moffatt S.D., Demers P., Robbins R.C., et al. Lung transplantation: a decade of experience. J Heart Lung Transplant 25 (2006) 145-151
2. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
3. Wallace A.H., Bellamy C.O.C., Rassl D.M., and Harrison D.J. Transplant histopathology for the general histopathologist. Histopathology 43 (2003) 313-322
4. Mauck K.A., and Hosenpud J.D. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung transplantation. J Heart Lung Transplant 15 (1996) 709-714
5. Tikkanen J.M., Hollmén M., Nykanen A.I., et al. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Am J Crit Care Med 174 (2006) 1145-1152
6. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol 36 (2004) 986-990
7. Bosman F.T., and Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 200 (2003) 423-428
8. Erickson H.P. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr Opin Cell Biol 5 (1993) 869-876
9. Hagios C., Koch M., Spring J., Chiquet M., Chiquet-Ehrismann R., and Tenascin Y. A protein of novel domain structure is secreted by differentiated fibroblasts of muscle connective tissue. J Cell Biol 134 (1996) 1499-1512
10. Chiquet-Ehrishmann R., Mackie E.J., Pearson C.A., and Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47 (1986) 131-139
11. Mackie E.J., Halfter W., and Liverani D. Induction of tenascin in healing wounds. J Cell Biol 107 (1988) 2757-2767
12. Esposito I., Penzel R., Chaib-Harrireche M., et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol 208 (2006) 673-685
13. Kaarteenaho-Wiik R., Kinnula V., Herva R., et al. Distribution and mRNA expression of tenascin-C in developing human lung. Am J Respir Cell Mol Biol 25 (2001) 341-346
14. Koukoulis G.K., Gould V.E., Bhattacharyya A., et al. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum Pathol 22 (1991) 636-643
15. McGovan S.E. Extracellular matrix and the regulation of lung development and repair. FASEB J 6 (1992) 2895-2904
16. Karjalainen E.M., Lindqvist A., Laitinen L.A., et al. Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma. Respir Med 97 (2003) 1045-1051
17. Soini Y., Paakko P., Nuorva K., et al. Tenascin immunoreactivity in lung tumors. Am J Clin Pathol 100 (1993) 145-150
18. Paakko P., Kaarteenaho-Wiik R., Pollanen R., and Soini Y. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med 161 (2000) 967-972
19. Coito A.J., and Kupiec-Weglinski J.W. Extracellular matrix proteins in organ transplantation. Transplantation 69 (2000) 2465-2473
20. Riederer I., Silva-Barbosa S.D., Rodriques M.L., and Savino W. Local antilaminin antibody treatment alters the rejection pattern of murine cardiac allografts: correlation between cellular infiltration and extracellular matrix. Transplantation 74 (2002) 1515-1522
21. Ikonen T., Uusitalo M., Taskinen E., et al. Small airway obliteration in a new swine heterotopic lung and bronchial allograft model. J Heart Lung Transplant 17 (1998) 945-953
22. Paivaniemi O.E., Maasilta P.K., Alho H.S., Wolff C.H., and Salminen U.S. Cyclooxygenase-2 expression in experimental post-transplant obliterative bronchiolitis. J Pathol 204 (2004) 340-348
23. Maasilta P.K., Vainikka T.L.S., Alho H.S., and Salminen U.S. Immune cells in a heterotopic lamb-to-pig bronchial xenograft model. Transplant Int 18 (2005) 1100-1108
24. Tazelaar H., and Starnes V. Lung and heart-lung transplantation pathology. In: Kolbeck P.C., Markin R.S., and McManus B.M. (Eds). Transplant pathology (1994), American Society of Clinical Pathologists, Chicago, IL 219-240
25. Uusitalo M.H., Salminen U.S., Ikonen T.S., et al. Alloimmune injury preceding obliteration in porcine heterotopic lung implants: a histologic and immunologic study. Transplantation 54 (1999) 809-812
26. Fernandez F.G., Jaramillo A., Chen C., et al. Airway epithelium is the primary target of allograft rejection in murine obliterative airway disease. Am J Transplant 4 (2004) 319-325
27. Amin K., Ekberg-Jansson A., Löfdahl C.G., and Venge P. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax 58 (2003) 135-142
28. Flood-Page P., Menzies-Gow A., Phipps S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
29. Wadsworth S.J., Freyer A.M., Corteling R.L., and Hall I.P. Biosynthesized matrix provides a key role for survival signaling in bronchial epithelial cells. Am J Physiol (Lung Cell Mol Physiol) 286 (2004) 596-603
30. Kaarteenaho-Wiik R., Lakari E., Soini Y., et al. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases. J Histochem Cytochem 48 (2000) 1257-1268
31. Karjalainen E.M., Laitinen A., Sue-Chu M., et al. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med 161 (2000) 2086-2091
32. Laitinen A., Altraja A., Kampe M., et al. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 156 (1997) 951-958
33. El-Karef A., Yoshida T., Gabazza E.C., et al. Deficiency of tenascin-C attenuates liver fibrosis in immune-mediated chronic hepatitis in mice. J Pathol 211 (2007) 86-94
34. Zhao Y., Young S.L., and McIntosh J.C. Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. Am J Physiol 274 (1998) 1049-1057
35. Cho H.Y., Reddy S.P., Yamamoto M., and Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 18 (2004) 1258-1260
36. Chiquet M., Renedo A.S., Huber F., and Flück M. How do fibroblasts translate mechanical signals into changes in extracellular matrix production?. Matrix Biol 22 (2003) 73-80
37. Jones F.S., and Jones P.L. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dynam 218 (2000) 235-259
38. Hibino S., Kato K., Kudoh S., Yagita H., and Okumura K. Tenascin suppresses CD3-mediated T cell activation. Biochem Biophys Res Commun 250 (1998) 119-124
39. Puente Navazo M.D., Valmori D., and Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 167 (2001) 6431-6440
40. Ruegg C.R., Chiquet-Ehrismann R., and Alkan S.S. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci USA 86 (1989) 437-441